273 related articles for article (PubMed ID: 32043568)
1. CD96 functions as a co-stimulatory receptor to enhance CD8
Chiang EY; de Almeida PE; de Almeida Nagata DE; Bowles KH; Du X; Chitre AS; Banta KL; Kwon Y; McKenzie B; Mittman S; Cubas R; Anderson KR; Warming S; Grogan JL
Eur J Immunol; 2020 Jun; 50(6):891-902. PubMed ID: 32043568
[TBL] [Abstract][Full Text] [Related]
2. CD96 Is an Immune Checkpoint That Regulates CD8
Mittal D; Lepletier A; Madore J; Aguilera AR; Stannard K; Blake SJ; Whitehall VLJ; Liu C; Bettington ML; Takeda K; Long GV; Scolyer RA; Lan R; Siemers N; Korman A; Teng MWL; Johnston RJ; Dougall WC; Smyth MJ
Cancer Immunol Res; 2019 Apr; 7(4):559-571. PubMed ID: 30894377
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of CD96 surface molecule represents CD8⁺ T cells with dissimilar effector function during HIV-1 infection.
Eriksson EM; Keh CE; Deeks SG; Martin JN; Hecht FM; Nixon DF
PLoS One; 2012; 7(12):e51696. PubMed ID: 23272144
[TBL] [Abstract][Full Text] [Related]
5. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
[TBL] [Abstract][Full Text] [Related]
6. Interaction between nectin-1 and the human natural killer cell receptor CD96.
Holmes VM; Maluquer de Motes C; Richards PT; Roldan J; Bhargava AK; Orange JS; Krummenacher C
PLoS One; 2019; 14(2):e0212443. PubMed ID: 30759143
[TBL] [Abstract][Full Text] [Related]
7. Loss of CD96 Expression as a Marker of HIV-Specific CD8
Bunet R; Nayrac M; Ramani H; Sylla M; Durand M; Chartrand-Lefebvre C; Routy JP; Landay AL; Gauchat JF; Chomont N; Ancuta P; Kaufmann DE; Bernard N; Tremblay CL; El-Far M
Front Immunol; 2021; 12():673061. PubMed ID: 34122431
[TBL] [Abstract][Full Text] [Related]
8. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
[TBL] [Abstract][Full Text] [Related]
10. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
11. Coming of Age: CD96 Emerges as Modulator of Immune Responses.
Georgiev H; Ravens I; Papadogianni G; Bernhardt G
Front Immunol; 2018; 9():1072. PubMed ID: 29868026
[TBL] [Abstract][Full Text] [Related]
12. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
13. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
14. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
16. BCL9 regulates CD226 and CD96 checkpoints in CD8
Feng M; Wu Z; Zhou Y; Wei Z; Tian E; Mei S; Zhu Y; Liu C; He F; Li H; Xie C; Jin J; Dong J; Yang D; Yu K; Qian J; Lambrechts D; Wang MW; Zhu D
Signal Transduct Target Ther; 2021 Aug; 6(1):313. PubMed ID: 34417435
[TBL] [Abstract][Full Text] [Related]
17. Fcγ receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies.
Rogel A; Ibrahim FM; Thirdborough SM; Renart-Depontieu F; Birts CN; Buchan SL; Preville X; King EV; Al-Shamkhani A
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 35998045
[TBL] [Abstract][Full Text] [Related]
18. Perturbed CD8
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
[TBL] [Abstract][Full Text] [Related]
19. CD155/CD226-interaction impacts on the generation of innate CD8(+) thymocytes by regulating iNKT-cell differentiation.
Georgiev H; Ravens I; Shibuya A; Förster R; Bernhardt G
Eur J Immunol; 2016 Apr; 46(4):993-1003. PubMed ID: 26689152
[TBL] [Abstract][Full Text] [Related]
20. Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis.
Li W; Deng C; Yang H; Lu X; Li S; Liu X; Chen F; Chen L; Shu X; Zhang L; Liu Q; Wang G; Peng Q
Arthritis Res Ther; 2021 Jan; 23(1):15. PubMed ID: 33413573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
